Effects of dietary phosphate restriction and phosphate binders on FGF23 levels in CKD

Tamara Isakova, Allison Barchi-Chung, Gwen Enfield, Kelsey Smith, Gabriella Vargas, Jessica Houston, Huiliang Xie, Patricia Wahl, Eva Schiavenato, Austin Dosch, Orlando M. Gutiérrez, Jorge Diego, Oliver Lenz, Gabriel Contreras, Armando J Mendez, Rory B. Weiner, Myles Wolf

Research output: Contribution to journalArticle

78 Citations (Scopus)

Abstract

Background Elevated levels of fibroblast growth factor 23 (FGF23) are associated with increased risk of adverse outcomes in patients withCKD. Reducing dietary phosphate intake or absorptionmay decrease FGF23 levels, but data on the combined effects of dietary phosphate restriction and phosphate binders in CKD are limited. Design, setting, participants, & measurements In this 2×2 factorial, single-blinded, placebo-controlled, 3-month study, conducted between July 2009 and March 2012, 39 patients with CKD stages 3 or 4 and normal serum phosphate levels were randomly assigned to one of four groups: ad libitum diet plus lanthanum carbonate (LC) placebo (n=10), 900-mg phosphate diet plus LC placebo (n=10), ad libitum diet plus LC (n=11), or 900-mg phosphate diet plus LC (n=8). The dose of LC was 1000 mg three times daily with meals. Dietary restriction was accomplished with outpatient counseling. The primary end point was change in FGF23 levels from baseline. Results Compared with ad libitum diet, the 900-mg phosphate diet did not significantly reduce FGF23 levels (diet × time interaction, P=0.05). Compared with placebo, LC alone also did not significantly reduce FGF23 levels (LC × time interaction, P=0.21). However, the dual intervention significantly decreased FGF23 levels throughout the study period (diet × LC × time interaction, P=0.02), resulting in a 35% (95% confidence interval, 8%-62%) reduction by study end. Conclusion The combination of LC plus counseling for a phosphate-restricted diet decreased FGF23 levels in patients with CKD stages 324 and normal serum phosphate levels.

Original languageEnglish
Pages (from-to)1009-1018
Number of pages10
JournalClinical Journal of the American Society of Nephrology
Volume8
Issue number6
DOIs
StatePublished - Jun 7 2013

Fingerprint

Phosphates
Diet
Placebos
Counseling
lanthanum carbonate
fibroblast growth factor 23
Serum
Meals
Outpatients
Confidence Intervals

ASJC Scopus subject areas

  • Nephrology
  • Transplantation
  • Epidemiology
  • Critical Care and Intensive Care Medicine

Cite this

Isakova, T., Barchi-Chung, A., Enfield, G., Smith, K., Vargas, G., Houston, J., ... Wolf, M. (2013). Effects of dietary phosphate restriction and phosphate binders on FGF23 levels in CKD. Clinical Journal of the American Society of Nephrology, 8(6), 1009-1018. https://doi.org/10.2215/CJN.09250912

Effects of dietary phosphate restriction and phosphate binders on FGF23 levels in CKD. / Isakova, Tamara; Barchi-Chung, Allison; Enfield, Gwen; Smith, Kelsey; Vargas, Gabriella; Houston, Jessica; Xie, Huiliang; Wahl, Patricia; Schiavenato, Eva; Dosch, Austin; Gutiérrez, Orlando M.; Diego, Jorge; Lenz, Oliver; Contreras, Gabriel; Mendez, Armando J; Weiner, Rory B.; Wolf, Myles.

In: Clinical Journal of the American Society of Nephrology, Vol. 8, No. 6, 07.06.2013, p. 1009-1018.

Research output: Contribution to journalArticle

Isakova, T, Barchi-Chung, A, Enfield, G, Smith, K, Vargas, G, Houston, J, Xie, H, Wahl, P, Schiavenato, E, Dosch, A, Gutiérrez, OM, Diego, J, Lenz, O, Contreras, G, Mendez, AJ, Weiner, RB & Wolf, M 2013, 'Effects of dietary phosphate restriction and phosphate binders on FGF23 levels in CKD', Clinical Journal of the American Society of Nephrology, vol. 8, no. 6, pp. 1009-1018. https://doi.org/10.2215/CJN.09250912
Isakova, Tamara ; Barchi-Chung, Allison ; Enfield, Gwen ; Smith, Kelsey ; Vargas, Gabriella ; Houston, Jessica ; Xie, Huiliang ; Wahl, Patricia ; Schiavenato, Eva ; Dosch, Austin ; Gutiérrez, Orlando M. ; Diego, Jorge ; Lenz, Oliver ; Contreras, Gabriel ; Mendez, Armando J ; Weiner, Rory B. ; Wolf, Myles. / Effects of dietary phosphate restriction and phosphate binders on FGF23 levels in CKD. In: Clinical Journal of the American Society of Nephrology. 2013 ; Vol. 8, No. 6. pp. 1009-1018.
@article{d7b0db75fd084df29664babf7ad75bd4,
title = "Effects of dietary phosphate restriction and phosphate binders on FGF23 levels in CKD",
abstract = "Background Elevated levels of fibroblast growth factor 23 (FGF23) are associated with increased risk of adverse outcomes in patients withCKD. Reducing dietary phosphate intake or absorptionmay decrease FGF23 levels, but data on the combined effects of dietary phosphate restriction and phosphate binders in CKD are limited. Design, setting, participants, & measurements In this 2×2 factorial, single-blinded, placebo-controlled, 3-month study, conducted between July 2009 and March 2012, 39 patients with CKD stages 3 or 4 and normal serum phosphate levels were randomly assigned to one of four groups: ad libitum diet plus lanthanum carbonate (LC) placebo (n=10), 900-mg phosphate diet plus LC placebo (n=10), ad libitum diet plus LC (n=11), or 900-mg phosphate diet plus LC (n=8). The dose of LC was 1000 mg three times daily with meals. Dietary restriction was accomplished with outpatient counseling. The primary end point was change in FGF23 levels from baseline. Results Compared with ad libitum diet, the 900-mg phosphate diet did not significantly reduce FGF23 levels (diet × time interaction, P=0.05). Compared with placebo, LC alone also did not significantly reduce FGF23 levels (LC × time interaction, P=0.21). However, the dual intervention significantly decreased FGF23 levels throughout the study period (diet × LC × time interaction, P=0.02), resulting in a 35{\%} (95{\%} confidence interval, 8{\%}-62{\%}) reduction by study end. Conclusion The combination of LC plus counseling for a phosphate-restricted diet decreased FGF23 levels in patients with CKD stages 324 and normal serum phosphate levels.",
author = "Tamara Isakova and Allison Barchi-Chung and Gwen Enfield and Kelsey Smith and Gabriella Vargas and Jessica Houston and Huiliang Xie and Patricia Wahl and Eva Schiavenato and Austin Dosch and Guti{\'e}rrez, {Orlando M.} and Jorge Diego and Oliver Lenz and Gabriel Contreras and Mendez, {Armando J} and Weiner, {Rory B.} and Myles Wolf",
year = "2013",
month = "6",
day = "7",
doi = "10.2215/CJN.09250912",
language = "English",
volume = "8",
pages = "1009--1018",
journal = "Clinical journal of the American Society of Nephrology : CJASN",
issn = "1555-9041",
publisher = "American Society of Nephrology",
number = "6",

}

TY - JOUR

T1 - Effects of dietary phosphate restriction and phosphate binders on FGF23 levels in CKD

AU - Isakova, Tamara

AU - Barchi-Chung, Allison

AU - Enfield, Gwen

AU - Smith, Kelsey

AU - Vargas, Gabriella

AU - Houston, Jessica

AU - Xie, Huiliang

AU - Wahl, Patricia

AU - Schiavenato, Eva

AU - Dosch, Austin

AU - Gutiérrez, Orlando M.

AU - Diego, Jorge

AU - Lenz, Oliver

AU - Contreras, Gabriel

AU - Mendez, Armando J

AU - Weiner, Rory B.

AU - Wolf, Myles

PY - 2013/6/7

Y1 - 2013/6/7

N2 - Background Elevated levels of fibroblast growth factor 23 (FGF23) are associated with increased risk of adverse outcomes in patients withCKD. Reducing dietary phosphate intake or absorptionmay decrease FGF23 levels, but data on the combined effects of dietary phosphate restriction and phosphate binders in CKD are limited. Design, setting, participants, & measurements In this 2×2 factorial, single-blinded, placebo-controlled, 3-month study, conducted between July 2009 and March 2012, 39 patients with CKD stages 3 or 4 and normal serum phosphate levels were randomly assigned to one of four groups: ad libitum diet plus lanthanum carbonate (LC) placebo (n=10), 900-mg phosphate diet plus LC placebo (n=10), ad libitum diet plus LC (n=11), or 900-mg phosphate diet plus LC (n=8). The dose of LC was 1000 mg three times daily with meals. Dietary restriction was accomplished with outpatient counseling. The primary end point was change in FGF23 levels from baseline. Results Compared with ad libitum diet, the 900-mg phosphate diet did not significantly reduce FGF23 levels (diet × time interaction, P=0.05). Compared with placebo, LC alone also did not significantly reduce FGF23 levels (LC × time interaction, P=0.21). However, the dual intervention significantly decreased FGF23 levels throughout the study period (diet × LC × time interaction, P=0.02), resulting in a 35% (95% confidence interval, 8%-62%) reduction by study end. Conclusion The combination of LC plus counseling for a phosphate-restricted diet decreased FGF23 levels in patients with CKD stages 324 and normal serum phosphate levels.

AB - Background Elevated levels of fibroblast growth factor 23 (FGF23) are associated with increased risk of adverse outcomes in patients withCKD. Reducing dietary phosphate intake or absorptionmay decrease FGF23 levels, but data on the combined effects of dietary phosphate restriction and phosphate binders in CKD are limited. Design, setting, participants, & measurements In this 2×2 factorial, single-blinded, placebo-controlled, 3-month study, conducted between July 2009 and March 2012, 39 patients with CKD stages 3 or 4 and normal serum phosphate levels were randomly assigned to one of four groups: ad libitum diet plus lanthanum carbonate (LC) placebo (n=10), 900-mg phosphate diet plus LC placebo (n=10), ad libitum diet plus LC (n=11), or 900-mg phosphate diet plus LC (n=8). The dose of LC was 1000 mg three times daily with meals. Dietary restriction was accomplished with outpatient counseling. The primary end point was change in FGF23 levels from baseline. Results Compared with ad libitum diet, the 900-mg phosphate diet did not significantly reduce FGF23 levels (diet × time interaction, P=0.05). Compared with placebo, LC alone also did not significantly reduce FGF23 levels (LC × time interaction, P=0.21). However, the dual intervention significantly decreased FGF23 levels throughout the study period (diet × LC × time interaction, P=0.02), resulting in a 35% (95% confidence interval, 8%-62%) reduction by study end. Conclusion The combination of LC plus counseling for a phosphate-restricted diet decreased FGF23 levels in patients with CKD stages 324 and normal serum phosphate levels.

UR - http://www.scopus.com/inward/record.url?scp=84878885412&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84878885412&partnerID=8YFLogxK

U2 - 10.2215/CJN.09250912

DO - 10.2215/CJN.09250912

M3 - Article

C2 - 23471131

AN - SCOPUS:84878885412

VL - 8

SP - 1009

EP - 1018

JO - Clinical journal of the American Society of Nephrology : CJASN

JF - Clinical journal of the American Society of Nephrology : CJASN

SN - 1555-9041

IS - 6

ER -